Author Topic: (Abst.)Discontinuing DMT in middle-aged MS patients: First-line drugs vs. Tysabri  (Read 78 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9545
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed, March 12, 2017:

Mult Scler Relat Disord. 2017 Feb;12:82-87.

Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab

Fagius J1, Feresiadou A2, Larsson EM3, Burman J2.

Author information

Department of Neuroscience, Uppsala University, Uppsala, Sweden. Electronic address:
Department of Neuroscience, Uppsala University, Uppsala, Sweden.
Department of Surgical Sciences/Radiology, Uppsala University, Uppsala, Sweden.


Several disease-modifying drugs (DMD) are available for the treatment of MS, and most patients with relapsing-remitting disease are currently treated. Data on when and how DMD treatment can be safely discontinued are scarce.


Fifteen MS patients, treated with natalizumab for >5 years without clinical and radiological signs of inflammatory disease activity, suspended treatment and were monitored with MRI examinations and clinical follow-up to determine recurrence of disease activity. This group was compared with a retrospectively analysed cohort comprising 55 MS patients treated with first-line DMDs discontinuing therapy in the time period of 1998-2015 after an analogous stable course.


Natalizumab discontinuers were followed for on average 19 months, and follow-up data for 56 months were available for first-line DMD quitters. Two-thirds of natalizumab treated patients experienced recurrent inflammatory disease activity, and one third had recurrence of rebound character. In contrast, 35% of first-line DMD quitters had mild recurrent disease activity, and no one exhibited rebound.


Withdrawal of a first-line DMD after prolonged treatment in middle-aged MS patients with stable disease appears to be relatively safe, while natalizumab withdrawal in a similar group of patients cannot be safely done without starting alternative therapy.
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post May 16, 2017, 12:21:07 pm
by agate
0 Replies
Last post November 14, 2019, 09:25:59 pm
by agate
0 Replies
Last post January 25, 2022, 09:03:25 pm
by agate
0 Replies
Last post April 30, 2022, 09:47:47 pm
by agate
0 Replies
Last post May 27, 2022, 09:38:47 pm
by agate